FOLD - Amicus Therapeutics Inc Stock Price, Fair Value and News

9.58USD+0.08 (+0.84%)Market Closed

Market Summary

USD9.58+0.08

Market Closed

0.84%

FOLD Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

FOLD Stock Price

View Fullscreen

FOLD RSI Chart

FOLD Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-19.29

Price/Sales (Trailing)

6.7

EV/EBITDA

-37.22

Price/Free Cashflow

-32.24

FOLD Price/Sales (Trailing)

FOLD Profitability

Operating Margin

97.20%

EBT Margin

-33.17%

Return on Equity

-112.53%

Return on Assets

-20.38%

Free Cashflow Yield

-3.1%

FOLD Fundamentals

FOLD Revenue

Revenue (TTM)

423.5M

Rev. Growth (Yr)

27.97%

Rev. Growth (Qtr)

-4.07%

FOLD Earnings

Earnings (TTM)

-147.1M

Earnings Growth (Yr)

8.53%

Earnings Growth (Qtr)

-43.07%

Breaking Down FOLD Revenue

Last 7 days

3.8%

Last 30 days

-9.2%

Last 90 days

-30.4%

Trailing 12 Months

-16.8%

How does FOLD drawdown profile look like?

FOLD Financial Health

Current Ratio

3.03

Debt/Equity

2.97

Debt/Cashflow

-0.21

FOLD Investor Care

Shares Dilution (1Y)

4.08%

Diluted EPS (TTM)

-0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	423.5M	0	0	0
2023	336.8M	350.6M	372.4M	399.4M
2022	317.8M	321.1M	323.3M	329.2M
2021	266.8M	281.8M	293.9M	305.5M
2020	208.7M	226.9M	245.6M	260.9M
2019	108.6M	131.4M	159.6M	182.2M
2018	49.5M	63.6M	73.3M	91.2M
2017	9.1M	16.3M	25.0M	36.9M
2016	0	0	2.9M	5.3M
2014	11.5M	8.1M	4.7M	1.2M
2013	0	0	0	15.0M
2012	23.2M	29.8M	24.0M	18.4M
2011	47.2M	38.6M	30.0M	21.4M
2010	0	0	0	55.8M
2009	0	0	0	64.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amicus Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	campbell bradley l	acquired	64,575	8.61	7,500	president and ceo
May 01, 2024	campbell bradley l	sold	-75,523	10.0698	-7,500	president and ceo
Apr 15, 2024	prout samantha	sold (taxes)	-74,907	10.66	-7,027	chief accounting officer
Apr 01, 2024	campbell bradley l	acquired	64,575	8.61	7,500	president and ceo
Apr 01, 2024	campbell bradley l	sold	-87,495	11.6661	-7,500	president and ceo
Mar 15, 2024	campbell bradley l	sold (taxes)	-153,545	11.48	-13,375	president and ceo
Mar 07, 2024	sblendorio glenn	acquired	42,000	2.8	15,000	-
Mar 05, 2024	mcglynn margaret g	acquired	21,000	2.8	7,500	-
Mar 05, 2024	raab michael	acquired	42,000	2.8	15,000	-
Mar 05, 2024	mcglynn margaret g	sold	-100,500	13.4	-7,500	-

Which funds bought or sold FOLD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	reduced	-50.07	-16,835,300	11,918,700	0.30%
May 16, 2024	COMERICA BANK	reduced	-9.23	-361,666	1,105,840	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-3.96	-686,877	2,701,840	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-43.82	-1,986,520	1,735,980	-%
May 16, 2024	Ancora Advisors LLC	unchanged	-	-6,493	31,735	-%
May 15, 2024	ORBIMED ADVISORS LLC	reduced	-29.24	-4,719,010	6,718,130	0.12%
May 15, 2024	Squarepoint Ops LLC	new	-	2,958,030	2,958,030	-%
May 15, 2024	Integrated Wealth Concepts LLC	added	0.2	-46,989	229,290	-%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	new	-	194,240	194,240	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-91.58	-353,070	26,540	-%

Are Funds Buying or Selling FOLD?

Are funds buying FOLD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FOLD

No. of Funds

Unveiling Amicus Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	perceptive advisors llc	9.6%	28,057,456	SC 13G/A
Feb 14, 2024	redmile group, llc	7.3%	21,957,926	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	9.3%	27,400,000	SC 13G/A
Feb 13, 2024	vanguard group inc	9.72%	28,492,486	SC 13G/A
Feb 08, 2024	wellington management group llp	5.18%	15,190,024	SC 13G
Jan 26, 2024	blackrock inc.	7.8%	22,985,442	SC 13G/A
Jan 08, 2024	jpmorgan chase & co	5.9%	17,502,680	SC 13G
Dec 08, 2023	morgan stanley	4.2%	12,303,701	SC 13G/A
Feb 14, 2023	avoro capital advisors llc	9.5%	26,800,000	SC 13G/A
Feb 14, 2023	redmile group, llc	9.9%	28,599,494	SC 13G/A

Recent SEC filings of Amicus Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 01, 2024	144	Notice of Insider Sale Intent
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 16, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Amicus Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Amicus Therapeutics Inc News

Latest updates

Amicus Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-4.1%	110,403,000	115,082,000	103,501,000	94,503,000	86,270,000	88,096,000	81,691,000	80,731,000	78,715,000	82,154,000	79,545,000	77,413,000	66,402,000	70,571,000	67,437,000	62,353,000	60,525,000	55,293,000	48,768,000	44,130,000	34,046,000
Gross Profit	-6.7%	96,836,000	103,758,000	93,555,000	85,389,000	79,328,000	78,712,000	68,255,000	72,534,000	71,133,000	74,303,000	67,849,000	69,033,000	59,863,000	61,154,000	59,038,000	55,677,000	53,973,000	48,348,000	43,172,000	38,763,000	29,991,000
Operating Expenses	15.9%	124,557,000	107,450,000	110,578,000	104,249,000	116,964,000	121,040,000	102,095,000	133,147,000	146,472,000	146,449,000	110,248,000	107,867,000	112,918,000	125,989,000	111,799,000	107,022,000	132,030,000	137,371,000	100,477,000	115,193,000	111,270,000
S&GA Expenses	25.3%	88,029,000	70,239,000	65,651,000	65,423,000	73,957,000	54,274,000	47,272,000	53,379,000	58,116,000	57,601,000	46,107,000	42,276,000	46,726,000	43,685,000	37,850,000	34,657,000	40,215,000	43,300,000	39,680,000	42,578,000	44,303,000
EBITDA Margin	17.1%	-0.19	-0.23	-0.36	-0.40	-0.50	-0.61	-0.66	-0.73	-0.69	-0.66	-0.66	-0.74	-	-	-	-	-	-	-	-	-
Interest Expenses	-3.0%	12,436,000	12,827,000	12,986,000	12,492,000	11,844,000	11,095,000	9,620,000	8,257,000	8,147,000	8,164,000	8,165,000	8,150,000	7,992,000	8,277,000	6,784,000	3,635,000	3,729,000	3,767,000	4,026,000	4,625,000	6,454,000
Income Taxes	121.5%	4,836,000	2,183,000	-3,128,000	2,715,000	-287,000	-14,214,000	4,023,000	911,000	3,809,000	2,981,000	-182,000	4,525,000	1,582,000	-2,193,000	727,000	3,703,000	361,000	-156,000	-251,000	717,000	168,000
Earnings Before Taxes	-37.7%	-43,583,000	-31,660,000	-24,705,000	-40,517,000	-53,219,000	-70,079,000	-29,263,000	-61,246,000	-81,451,000	-80,296,000	-50,476,000	-46,700,000	-64,082,000	-73,594,000	-63,284,000	-48,789,000	-88,587,000	-89,885,000	-62,060,000	-83,834,000	-120,131,000
EBT Margin	11.8%	-0.33	-0.38	-0.51	-0.55	-0.63	-0.74	-0.78	-0.85	-0.81	-0.79	-0.80	-0.88	-	-	-	-	-	-	-	-	-
Net Income	-43.1%	-48,419,000	-33,843,000	-21,577,000	-43,232,000	-52,932,000	-55,865,000	-33,286,000	-62,157,000	-85,260,000	-83,277,000	-50,294,000	-51,225,000	-65,664,000	-71,401,000	-64,011,000	-52,492,000	-88,948,000	-89,729,000	-61,809,000	-84,551,000	-120,299,000
Net Income Margin	8.5%	-0.35	-0.38	-0.47	-0.53	-0.61	-0.72	-0.82	-0.87	-0.85	-0.82	-0.81	-0.90	-	-	-	-	-	-	-	-	-
Free Cashflow	-1924.3%	-31,506,000	1,727,000	-39,912,000	-18,335,000	-20,011,000	-83,449,000	-11,489,000	-16,217,000	-59,186,000	-72,274,000	-24,590,000	-36,289,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.2%	722	778	764	730	701	724	760	801	827	905	957	787	810	887	901	701	738	850	882	918	765
Current Assets	-10.7%	431	483	463	433	400	424	459	498	519	597	651	481	503	579	585	384	408	520	577	635	483
Cash Equivalents	-13.8%	213	247	263	211	161	149	278	236	233	245	386	177	185	166	211	165	123	146	166	221	96.00
Inventory	1.8%	61.00	60.00	57.00	51.00	27.00	24.00	13.00	21.00	24.00	27.00	22.00	24.00	19.00	20.00	16.00	13.00	13.00	14.00	9.00	10.00	8.00
Net PPE	2.4%	32.00	32.00	31.00	30.00	31.00	31.00	32.00	34.00	35.00	42.00	42.00	42.00	43.00	44.00	45.00	47.00	48.00	48.00	35.00	15.00	13.00
Goodwill	0%	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198	198
Liabilities	-4.3%	591	618	631	619	598	601	627	627	588	598	580	573	559	600	580	340	336	374	334	318	313
Current Liabilities	-15.3%	142	168	169	159	138	139	165	165	130	146	121	112	100	130	112	108	92.00	129	93.00	90.00	66.00
Long Term Debt	0.1%	388	388	394	393	393	392	391	391	390	389	389	390	390	389	389	-	-	150	-	-	-
Shareholder's Equity	-18.4%	131	160	133	112	103	123	133	173	239	307	377	214	251	286	320	361	403	476	548	600	452
Retained Earnings	-1.2%	-2,732	-2,700	-2,700	-2,628	-2,585	-2,532	-2,500	-2,443	-2,381	-2,295	-2,212	-2,162	-2,100	-2,045	-1,974	-1,910	-1,900	-1,768	-1,678	-1,600	-1,532
Additional Paid-In Capital	0.6%	2,854	2,836	2,787	2,733	2,692	2,665	2,645	2,631	2,618	2,595	2,580	2,364	2,351	2,309	2,275	2,251	2,238	2,227	2,211	2,201	1,971
Accumulated Depreciation	4.5%	27.00	25.00	25.00	24.00	23.00	22.00	23.00	22.00	21.00	20.00	19.00	17.00	16.00	14.00	24.00	21.00	19.00	18.00	18.00	17.00	16.00
Shares Outstanding	0.9%	296	294	291	287	283	281	289	292	288	271	266	265	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	3,557	-	-	-	2,980	-	-	-	2,541	-	-	-	3,851	-	-	-	3,147	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-958.7%	-29,695	3,458	-38,347	-16,133	-18,069	-80,772	-11,626	-15,862	-58,315	-70,514	-23,700	-35,923	-72,354	-49,822	-42,008	-33,518	-107,942	-57,832	-55,553	-58,485	-78,546
Share Based Compensation	70.2%	30,803	18,095	16,511	16,577	34,894	18,626	14,772	12,463	30,651	13,907	11,841	11,736	20,354	12,239	15,908	8,408	12,596	12,908	8,843	9,935	12,744
Cashflow From Investing	131.5%	7,537	-23,957	35,765	50,001	36,255	-66,704	74,515	26,292	58,213	-68,089	34,572	25,713	86,565	-22,776	-154,061	70,012	93,246	26,963	3,193	-15,068	80,065
Cashflow From Financing	-262.1%	-13,309	8,210	37,619	23,673	-7,825	557	-559	693	-8,154	-104	201,113	2,235	8,829	21,548	238,711	4,086	-1,487	3,191	523	196,404	17,384

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FOLD Income Statement

2024-03-31

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net product sales	$ 110,403	$ 86,270
Cost of goods sold	13,567	6,942
Gross profit	96,836	79,328
Operating expenses:
Research and development	28,329	41,499
Selling, general, and administrative	88,029	73,957
Changes in fair value of contingent consideration payable	0	251
Restructuring charges	6,045	0
Depreciation and amortization	2,154	1,257
Total operating expenses	124,557	116,964
Loss from operations	(27,721)	(37,636)
Other expense:
Interest income	1,540	2,199
Interest expense	(12,436)	(11,844)
Other expense	(4,966)	(5,938)
Loss before income tax	(43,583)	(53,219)
Income tax (expense) benefit	(4,836)	287
Net loss attributable to common stockholders	$ (48,419)	$ (52,932)
Net loss attributable to common stockholders per common share - basic (in dollars per share)	$ (0.16)	$ (0.18)
Net loss attributable to common stockholders per common share — diluted (in dollars per share)	$ (0.16)	$ (0.18)
Weighted average common shares outstanding - basic (in shares)	302,903,009	291,336,750
Weighted average common shares outstanding - diluted (in shares)	302,903,009	291,336,750

FOLD Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 209,761	$ 246,994
Investments in marketable securities	29,842	39,206
Accounts receivable	76,433	87,632
Inventories	60,759	59,696
Prepaid expenses and other current assets	54,444	49,533
Total current assets	431,239	483,061
Operating lease right-of-use assets, net	23,003	26,312
Property and equipment, less accumulated depreciation of $26,563 and $25,429 at March 31, 2024 and December 31, 2023, respectively	32,421	31,667
Intangible assets, less accumulated amortization of $3,328 and $2,510 at March 31, 2024 and December 31, 2023, respectively	19,672	20,490
Goodwill	197,797	197,797
Other non-current assets	17,657	18,553
Total Assets	721,789	777,880
Current liabilities:
Accounts payable	9,210	15,120
Accrued expenses and other current liabilities	124,622	144,245
Operating lease liabilities	8,270	8,324
Total current liabilities	142,102	167,689
Long-term debt	388,391	387,858
Operating lease liabilities	47,831	48,877
Other non-current liabilities	12,771	13,282
Total liabilities	591,095	617,706
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value, 500,000,000 shares authorized, 296,159,417 and 293,594,209 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	2,922	2,918
Additional paid-in capital	2,853,550	2,836,018
Accumulated other comprehensive loss:
Foreign currency translation adjustment	6,847	5,429
Unrealized loss on available-for-sale securities	(203)	(188)
Warrants	71	71
Accumulated deficit	(2,732,493)	(2,684,074)
Total stockholders’ equity	130,694	160,174
Total Liabilities and Stockholders’ Equity	$ 721,789	$ 777,880

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

CEO	Mr. Bradley L. Campbell M.B.A.
WEBSITE	https://amicusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	484

Amicus Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Amicus Therapeutics Inc? What does FOLD stand for in stocks?

FOLD is the stock ticker symbol of Amicus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amicus Therapeutics Inc (FOLD)?

As of Fri May 17 2024, market cap of Amicus Therapeutics Inc is 2.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FOLD stock?

You can check FOLD's fair value in chart for subscribers.

What is the fair value of FOLD stock?

You can check FOLD's fair value in chart for subscribers. The fair value of Amicus Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amicus Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FOLD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amicus Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FOLD is over valued or under valued. Whether Amicus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Amicus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FOLD.

What is Amicus Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, FOLD's PE ratio (Price to Earnings) is -19.29 and Price to Sales (PS) ratio is 6.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FOLD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amicus Therapeutics Inc's stock?

In the past 10 years, Amicus Therapeutics Inc has provided 0.164 (multiply by 100 for percentage) rate of return.